Clinical Trials | March 23, 2024
AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer
Combination shows consistent benefit across prespecified post-progression outcomes
Combination shows consistent benefit across prespecified post-progression outcomes
The drug will target specific genetic mutations prevalent in certain types of cancers
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
The company has received five final approvals
Innovent will supply sintilimab for the collaborated clinical trial
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Subscribe To Our Newsletter & Stay Updated
